IntermediateSexual WellnessMelanocortin

PT-141

Bremelanotide · MC4R Agonist

A melanocortin receptor agonist that works centrally through the brain — not the vascular system — to enhance sexual desire and arousal. Studied for both men and women, with FDA approval (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women.

Researched Wellness Applications

✓ Sexual desire & libido enhancement

✓ Arousal & sensitivity support

✓ Erectile function support (men)

✓ Hypoactive sexual desire disorder (women)

✓ Central CNS-mediated sexual response

Assessment Options

$299

No subscription required · Physician reviewed

Start Physician Review →

Physician review required · Ships in 48h after approval · All 50 states

Split payments available with affirm — 0% interest options

What Is It?

PT-141 explained simply

PT-141 (Bremelanotide) is a synthetic analog of alpha-MSH (alpha-Melanocyte Stimulating Hormone) that acts directly on melanocortin receptors in the brain — specifically MC3R and MC4R — to activate the neural pathways involved in sexual motivation and arousal. Unlike PDE5 inhibitors (such as Viagra or Cialis), PT-141 does not work through the vascular system. It targets the central nervous system, addressing the root neurological component of sexual response.

This central mechanism makes PT-141 uniquely effective for both men and women. The FDA approved Bremelanotide (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — one of the few FDA-approved pharmacological treatments for female sexual dysfunction. Research in men has also demonstrated significant improvements in sexual desire and erectile function.

PT-141 is typically administered as a subcutaneous injection 45 minutes to 1.5 hours before anticipated sexual activity. It is a situational protocol — not a daily administration — making it distinct from most other peptide regimens.

FDA

Approved (as Vyleesi)

CNS

Central mechanism of action

Situational injection

Mechanism

How PT-141 works

Central Melanocortin Activation

PT-141 binds to melanocortin receptors — particularly MC3R and MC4R — in the hypothalamus and limbic system. These receptors are part of the brain's reward and motivation circuitry and play a direct role in regulating sexual behavior. By activating these pathways, PT-141 increases sexual motivation, desire, and subjective arousal at the neurological level.

How It Differs from PDE5 Inhibitors

Drugs like sildenafil (Viagra) work by relaxing vascular smooth muscle to increase blood flow — a peripheral, mechanical mechanism. PT-141 works upstream, in the brain, addressing the neurological drive for sexual activity. This is why it can be effective in cases where vascular-focused medications have not — including psychogenic erectile dysfunction and female sexual arousal disorders with no vascular component.

Clinical Research

PT-141 has been studied in randomized controlled trials for HSDD in women and erectile dysfunction in men. The FDA approval of Bremelanotide (Vyleesi) in 2019 was based on placebo-controlled Phase 3 clinical data. Research in men has shown increases in both spontaneous erections and reports of sexual desire. Administration is situational — typically 45 minutes to 90 minutes before activity — rather than daily.

Administration

PT-141 is administered via subcutaneous injection. Timing, dosage, and frequency are determined through the BRAVO1 physician review process based on your individual health profile and goals. Do not self-administer any peptide protocol without physician oversight.

FAQ

Questions about PT-141

PT-141 is studied for both men and women experiencing reduced sexual desire, arousal difficulties, or sexual dysfunction with a neurological/psychological component. It is FDA-approved for HSDD in premenopausal women. Appropriateness is assessed individually through our physician review process.

No. Viagra (sildenafil) works peripherally by increasing blood flow to genital tissue. PT-141 works centrally — in the brain — by activating melanocortin receptors involved in sexual desire and motivation. They have different mechanisms, different target populations, and can complement each other in some protocols. PT-141 also works for women, whereas PDE5 inhibitors are not approved for female sexual dysfunction.

PT-141 is typically administered 45 minutes to 1.5 hours before anticipated sexual activity. It is not a daily protocol — it is used situationally. Specific timing guidance is included with every order and reviewed during physician approval.

All BRAVO1 orders ship within 48 hours of physician approval from our temperature-controlled facility. Delivery is available to all 50 states. You'll receive tracking confirmation as soon as your order dispatches.

Ready to begin?

Start the physician review process for PT-141. Ships within 48 hours of approval to all 50 states.

Start Physician Review →

Physician Reviewed

Ships to All 50 States

48-Hour Fulfillment

LegitScript Certified

Licensed Pharmacy Partner

Partner Pharmacy

PerfectRx

Phone(866) 866-6806

Emailinfo@perfectrx.com

Address5810 Long Prairie Rd
Flower Mound, TX 75028

Service Availability

United States

Serving all 50 states. Products are fulfilled through our licensed compounding pharmacy partner and shipped directly to patients following physician approval.

Provider Licensure Disclosures

Arora Health and Aesthetics · Dr. Sean Arora

Vermont

License 042.0016085-COMPExpires 11/31/2026

Rhode Island

License MD20370Expires 06/30/2026

Massachusetts

License 1018420Expires 07/20/2027